Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-8895a in Subjects With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs DS 8895 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 10 Apr 2017 Status changed from active, no longer recruiting to completed.
- 13 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Jan 2016 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.